Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
September 09, 2024 07:00 ET
|
Autonomix Medical, Inc.
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction...
SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference
September 05, 2024 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
September 04, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage medical device company developing proprietary solutions to reduce...
Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
August 21, 2024 08:30 ET
|
Autonomix Medical, Inc.
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company’s ongoing proof-of-concept (PoC) human...
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 13, 2024 16:38 ET
|
SeaStar Medical Holding Corporation
DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
August 13, 2024 08:00 ET
|
Autonomix Medical, Inc.
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
August 02, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
July 24, 2024 08:00 ET
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA regulatory...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
July 22, 2024 09:05 ET
|
Autonomix Medical, Inc.
Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...